Journal Article

Troponin in acute chest pain to risk stratify and guide effective use of computed tomography coronary angiography (TARGET-CTCA): a randomised controlled trial

Goodacre, Steve, Thokala, Praveen, Tuck, Chris, Mills, Nicholas L., Cranley, Denise, Newby, David E., Byrne, John, Keerie, Catriona, Wereski, Ryan, Bularga, Anda, Lee, Kuan Ken, Taggart, Caelan, Lowe, David, O’Brien, Rachel, Ferry, Amy V., Roditi, Giles, Williams, Michelle C., Gray, Alasdair J., Lowry, Matthew T. H., Norrie, John

2023

Overview

Background The majority of patients with suspected acute coronary syndrome presenting to the emergency department will be discharged once myocardial infarction has been ruled out, although a proportion will have unrecognised coronary artery disease. In this setting, high-sensitivity cardiac troponin identifies those at increased risk of future cardiac events. In patients with intermediate cardiac troponin concentrations in whom myocardial infarction has been ruled out, this trial aims to investigate whether outpatient computed tomography coronary angiography (CTCA) reduces subsequent myocardial infarction or cardiac death. Methods TARGET-CTCA is a multicentre prospective randomised open label with blinded endpoint parallel group event driven trial. After myocardial infarction and clear alternative diagnoses have been ruled out, participants with intermediate cardiac troponin concentrations (5 ng/L to 99th centile upper reference limit) will be randomised 1:1 to outpatient CTCA plus standard of care or standard of care alone. The primary endpoint is myocardial infarction or cardiac death. Secondary endpoints include clinical, patient-centred, process and cost-effectiveness. Recruitment of 2270 patients will give 90% power with a two-sided P value of 0.05 to detect a 40% relative risk reduction in the primary endpoint. Follow-up will continue until 97 primary outcome events have been accrued in the standard care arm with an estimated median follow-up of 36 months. Discussion This randomised controlled trial will determine whether high-sensitivity cardiac troponin-guided CTCA can improve outcomes and reduce subsequent major adverse cardiac events in patients presenting to the emergency department who do not have myocardial infarction. Trial registration ClinicalTrials.gov Identifier: NCT03952351. Registered on May 16, 2019.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Acute coronary syndrome / Acute coronary syndromes / Angiography / Biomedicine / Cardiac stress tests / Cardiovascular disease / Chest Pain / Computed Tomography Angiography / Computed tomography coronary angiography / Coronary Angiography / Coronary heart disease / Coronary vessels / Diagnosis / Electronic health records / Emergency medical care / Evaluation / Health Sciences / Heart attacks / High-sensitivity cardiac troponin / Hospitals / Humans / Informed consent / Lifestyles / Medical imaging / Medical records / Medicine / Medicine & Public Health / Myocardial Infarction - diagnostic imaging / Pain / Patient care planning / Prospective Studies / Quality of life / Questionnaires / Risk factors / Statistics for Life Sciences / Study Protocol / Tomography / Troponin / Vein & artery diseases